Search studies using keywords
1,851 Studies in the database containing data with -log p ≥ 0 (showing 81-100)
Pages: 1 2 3 4 5 6 7 8 9 10 >>
No data sets (in No Studies) added to Browser
Identifier Name Phenotype(s) Total p-values Related citationsAdd data sets to Browser Related data
HGVST1775 plus GWAS of Breast cancer (menopausal hormone therapy interaction) 
  • Lobular breast cancer (menopausal hormone therapy interaction)
  • Breast cancer (menopausal hormone therapy interaction)
4
HGVST1776 plus GWAS of Cocaine dependence 
  • Cocaine dependence (Symptom count, AA)
  • Cocaine dependence
  • Cocaine dependence (EA)
  • Cocaine dependence (Cocainei?1/2induced paranoia, AA)
  • Cocaine dependence (Symptom count)
  • Cocaine dependence (Symptom count, EA)
  • Cocaine dependence (Cocainei?1/2induced paranoia)
  • Cocaine dependence (AA)
14
HGVST1762 plus GWAS of Liver enzyme levels (alanine transaminase) 
  • Liver enzyme levels (aspartate transaminase)
  • Liver enzyme levels (alanine transaminase)
19
HGVST1763 plus GWAS of Osteoarthritis (hip) 
  • Osteoarthritis (hip) (Male-specifc)
  • Osteoarthritis (hip)
5
HGVST1764 plus GWAS of Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) 
  • Lung function (forced vital capacity) (AA)
  • Lung function (forced vital capacity) (EA)
  • Lung function (forced expiratory volume in 1 second) (EA)
  • Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) (AA)
  • Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) (AA)
  • Lung function (forced expiratory volume in 1 second)
  • Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) (EA)
  • Lung function (forced expiratory volume in 1 second) (AA)
  • Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) (EA)
35
HGVST1765 plus GWAS of Breast cancer 
  • Breast cancer
4
HGVST1766 plus GWAS of End-stage renal disease in Type 1 diabetics 
  • End-stage renal disease in Type 1 diabetics (Women)
1
HGVST1767 plus GWAS of Opioid sensitivity 
  • Opioid sensitivity (AA)
3
HGVST1768 plus GWAS of Schizophrenia, schizoaffective disorder or bipolar disorder 
  • Schizophrenia, schizoaffective disorder or bipolar disorder
5
HGVST1769 plus GWAS of Body mass index 
  • Body mass index
  • Fat body mass
  • Fat body mass (Adjusted by Lean body mass)
5
HGVST1770 plus GWAS of Psychosis (atypical) 
  • Psychosis (atypical)
10
HGVST1754 plus GWAS of Allergic dermatitis (nickel) 
  • Allergic dermatitis (nickel) (2-fold positive reaction cases)
  • Allergic dermatitis (nickel)
2
HGVST1755 plus GWAS of Periodontitis (CDC/AAP) 
  • Periodontitis (CDC/AAP) (Age 20-81 years)
  • Periodontitis (DPAL) (Age 20-81 years)
  • Periodontitis (Mean PAL) (Age 20-81 years)
  • Periodontitis (CDC/AAP) (Age 20-60 years)
  • Periodontitis (PAL4Q3) (Age 20-60 years)
  • Periodontitis (PAL4Q3) (Age 20-81 years)
  • Periodontitis (DPAL) (Age 20-60 years)
  • Periodontitis (Mean PAL) (Age 20-60 years)
91
HGVST1756 plus GWAS of Personality dimensions 
  • Personality dimensions (Openness)
  • Personality dimensions (Agreeableness)
  • Personality dimensions (Conscientiousness)
  • Personality dimensions (Neuroticism)
8
HGVST1757 plus GWAS of Axial length 
  • Axial length
21
HGVST1758 plus GWAS of Functional impairment in major depressive disorder, bipolar disorder and schizophrenia 
  • Functional impairment in major depressive disorder, bipolar disorder and schizophrenia (MCS)
  • Functional impairment in major depressive disorder, bipolar disorder and schizophrenia (PCS)
5
HGVST1759 plus GWAS of Social communication problems 
  • Social communication problems
4
HGVST1760 plus GWAS of Barrett's esophagus 
  • Barrett's esophagus
  • Esophageal adenocarcinoma
  • Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
25
HGVST1761 plus GWAS of Odorant perception (isobutyraldehyde) 
  • Odorant perception (i?1/2-damascenone)
  • Odorant perception (i?1/2-ionone)
  • Odorant perception (isobutyraldehyde)
3
HGVST1744 plus GWAS of Fasting insulin (interaction) 
  • Homeostasis model assessment of insulin resistance (interaction) (Protein (control))
  • Homeostasis model assessment of insulin resistance (interaction) (Carbohydrate)
  • Homeostasis model assessment of beta-cell function (interaction) (n-6 PUFA)
  • Homeostasis model assessment of beta-cell function (interaction) (Protein (control))
  • Fasting insulin (interaction) (Carbohydrate)
  • Fasting insulin (interaction) (Protein (control))
41